##gff-version 3								
##gvf-version 1.10								
##species https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=2697049								
#seqid	#source	#type	#start	#end	#score	#strand	#phase	#attributes
NC_045512.2	.	snp	186	186	.	+	.	ID=ID_0;Name=g.C-80T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=44;ao=2;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C-80T;aa_name=;hgvs_nt=NC_045512.2:g.80C>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.043478260869565216;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	222	222	.	+	.	ID=ID_1;Name=g.C-44T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=33;ao=13;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C-44T;aa_name=;hgvs_nt=NC_045512.2:g.44C>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.2826086956521739;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	241	241	.	+	.	ID=ID_2;Name=g.C-25T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C-25T;aa_name=;hgvs_nt=NC_045512.2:g.25C>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	503	503	.	+	.	ID=ID_3;Name=P80S;alias=P80S;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=33;ao=13;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C238T;aa_name=p.P80S;hgvs_nt=NC_045512.2:g.238C>T;hgvs_aa=YP_009724389.1:p.Pro80Ser;hgvs_alias=YP_009724389.1:Pro80Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.2826086956521739;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	599	599	.	+	.	ID=ID_4;Name=G112C;alias=G112C;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=45;ao=1;dp=46;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G334T;aa_name=p.G112C;hgvs_nt=NC_045512.2:g.334G>T;hgvs_aa=YP_009724389.1:p.Gly112Cys;hgvs_alias=YP_009724389.1:Gly112Cys;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021739130434782608;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	del	685	685	.	+	.	ID=ID_5;Name=K141_F143del;alias=K141_F143del;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=33;ao=13;dp=46;sample_size=49;Reference_seq=AAAGTCATTT;Variant_seq=A;nt_name=g.421_429delAAGTCATTT;aa_name=p.K141_F143del;hgvs_nt=NC_045512.2:g.421_429del;hgvs_aa=YP_009724389.1:p.Lys141_Phe143del;hgvs_alias=YP_009724389.1:Lys141_Phe143del;vcf_gene=ORF1ab;mutation_type=;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.2826086956521739;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	1059	1059	.	+	.	ID=ID_6;Name=T265I;alias=T85I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C794T;aa_name=p.T265I;hgvs_nt=NC_045512.2:g.794C>T;hgvs_aa=YP_009724389.1:p.Thr265Ile;hgvs_alias=YP_009724389.1:Thr85Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	1149	1149	.	+	.	ID=ID_7;Name=G295V;alias=G115V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=45;ao=1;dp=46;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G884T;aa_name=p.G295V;hgvs_nt=NC_045512.2:g.884G>T;hgvs_aa=YP_009724389.1:p.Gly295Val;hgvs_alias=YP_009724389.1:Gly115Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021739130434782608;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	1190	1190	.	+	.	ID=ID_8;Name=P309T;alias=P129T;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=43;ao=3;dp=46;sample_size=49;Reference_seq=C;Variant_seq=A;nt_name=g.C925A;aa_name=p.P309T;hgvs_nt=NC_045512.2:g.925C>A;hgvs_aa=YP_009724389.1:p.Pro309Thr;hgvs_alias=YP_009724389.1:Pro129Thr;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06521739130434782;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	1218	1218	.	+	.	ID=ID_9;Name=S318L;alias=S138L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=45;ao=1;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C953T;aa_name=p.S318L;hgvs_nt=NC_045512.2:g.953C>T;hgvs_aa=YP_009724389.1:p.Ser318Leu;hgvs_alias=YP_009724389.1:Ser138Leu;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021739130434782608;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	1851	1851	.	+	.	ID=ID_10;Name=I529T;alias=I349T;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=40;ao=6;dp=46;sample_size=49;Reference_seq=T;Variant_seq=C;nt_name=g.T1586C;aa_name=p.I529T;hgvs_nt=NC_045512.2:g.1586T>C;hgvs_aa=YP_009724389.1:p.Ile529Thr;hgvs_alias=YP_009724389.1:Ile349Thr;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.13043478260869565;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2571	2571	.	+	.	ID=ID_11;Name=P769H;alias=P589H;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=43;ao=3;dp=46;sample_size=49;Reference_seq=C;Variant_seq=A;nt_name=g.C2306A;aa_name=p.P769H;hgvs_nt=NC_045512.2:g.2306C>A;hgvs_aa=YP_009724389.1:p.Pro769His;hgvs_alias=YP_009724389.1:Pro589His;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06521739130434782;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2607	2607	.	+	.	ID=ID_12;Name=T781I;alias=T601I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=45;ao=1;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C2342T;aa_name=p.T781I;hgvs_nt=NC_045512.2:g.2342C>T;hgvs_aa=YP_009724389.1:p.Thr781Ile;hgvs_alias=YP_009724389.1:Thr601Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021739130434782608;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3037	3037	.	+	.	ID=ID_13;Name=F924F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C2772T;aa_name=p.F924F;hgvs_nt=NC_045512.2:g.2772C>T;hgvs_aa=YP_009724389.1:p.Phe924Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3231	3231	.	+	.	ID=ID_14;Name=G989V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=45;ao=1;dp=46;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G2966T;aa_name=p.G989V;hgvs_nt=NC_045512.2:g.2966G>T;hgvs_aa=YP_009724389.1:p.Gly989Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021739130434782608;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3304	3304	.	+	.	ID=ID_15;Name=E1013D;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=41;ao=5;dp=46;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G3039T;aa_name=p.E1013D;hgvs_nt=NC_045512.2:g.3039G>T;hgvs_aa=YP_009724389.1:p.Glu1013Asp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.10869565217391304;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3342	3342	.	+	.	ID=ID_16;Name=N1026S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=45;ao=1;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A3077G;aa_name=p.N1026S;hgvs_nt=NC_045512.2:g.3077A>G;hgvs_aa=YP_009724389.1:p.Asn1026Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021739130434782608;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3619	3619	.	+	.	ID=ID_17;Name=V1118V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=40;ao=6;dp=46;sample_size=49;Reference_seq=C;Variant_seq=A;nt_name=g.C3354A;aa_name=p.V1118V;hgvs_nt=NC_045512.2:g.3354C>A;hgvs_aa=YP_009724389.1:p.Val1118Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.13043478260869565;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3817	3817	.	+	.	ID=ID_18;Name=D1184D;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=25;ao=21;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C3552T;aa_name=p.D1184D;hgvs_nt=NC_045512.2:g.3552C>T;hgvs_aa=YP_009724389.1:p.Asp1184Asp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.45652173913043476;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	4162	4162	.	+	.	ID=ID_19;Name=V1299V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=44;ao=2;dp=46;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G3897T;aa_name=p.V1299V;hgvs_nt=NC_045512.2:g.3897G>T;hgvs_aa=YP_009724389.1:p.Val1299Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.043478260869565216;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	5184	5184	.	+	.	ID=ID_20;Name=P1640L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=44;ao=1;dp=45;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C4919T;aa_name=p.P1640L;hgvs_nt=NC_045512.2:g.4919C>T;hgvs_aa=YP_009724389.1:p.Pro1640Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.022222222222222223;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	5581	5581	.	+	.	ID=ID_21;Name=G1772G;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=44;ao=2;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C5316T;aa_name=p.G1772G;hgvs_nt=NC_045512.2:g.5316C>T;hgvs_aa=YP_009724389.1:p.Gly1772Gly;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.043478260869565216;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	6317	6317	.	+	.	ID=ID_22;Name=P2018T;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=45;ao=1;dp=46;sample_size=49;Reference_seq=C;Variant_seq=A;nt_name=g.C6052A;aa_name=p.P2018T;hgvs_nt=NC_045512.2:g.6052C>A;hgvs_aa=YP_009724389.1:p.Pro2018Thr;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021739130434782608;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	6500	6500	.	+	.	ID=ID_23;Name=P2079S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=44;ao=2;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C6235T;aa_name=p.P2079S;hgvs_nt=NC_045512.2:g.6235C>T;hgvs_aa=YP_009724389.1:p.Pro2079Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.043478260869565216;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	6717	6717	.	+	.	ID=ID_24;Name=S2151I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=45;ao=1;dp=46;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G6452T;aa_name=p.S2151I;hgvs_nt=NC_045512.2:g.6452G>T;hgvs_aa=YP_009724389.1:p.Ser2151Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021739130434782608;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	7869	7869	.	+	.	ID=ID_25;Name=S2535L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=45;ao=1;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C7604T;aa_name=p.S2535L;hgvs_nt=NC_045512.2:g.7604C>T;hgvs_aa=YP_009724389.1:p.Ser2535Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021739130434782608;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	8062	8062	.	+	.	ID=ID_26;Name=S2599S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=44;ao=2;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A7797G;aa_name=p.S2599S;hgvs_nt=NC_045512.2:g.7797A>G;hgvs_aa=YP_009724389.1:p.Ser2599Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.043478260869565216;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	8090	8090	.	+	.	ID=ID_27;Name=L2609F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=41;ao=5;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C7825T;aa_name=p.L2609F;hgvs_nt=NC_045512.2:g.7825C>T;hgvs_aa=YP_009724389.1:p.Leu2609Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.10869565217391304;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	8293	8293	.	+	.	ID=ID_28;Name=T2676T;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=44;ao=2;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C8028T;aa_name=p.T2676T;hgvs_nt=NC_045512.2:g.8028C>T;hgvs_aa=YP_009724389.1:p.Thr2676Thr;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.043478260869565216;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	8895	8895	.	+	.	ID=ID_29;Name=T2877I;alias=T114I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=42;ao=4;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C8630T;aa_name=p.T2877I;hgvs_nt=NC_045512.2:g.8630C>T;hgvs_aa=YP_009724389.1:p.Thr2877Ile;hgvs_alias=YP_009724389.1:Thr114Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.08695652173913043;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	9365	9365	.	+	.	ID=ID_30;Name=L3034L;alias=L271L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=41;ao=5;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C9100T;aa_name=p.L3034L;hgvs_nt=NC_045512.2:g.9100C>T;hgvs_aa=YP_009724389.1:p.Leu3034Leu;hgvs_alias=YP_009724389.1:Leu271Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.10869565217391304;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	9559	9559	.	+	.	ID=ID_31;Name=Y3098Y;alias=Y335Y;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=44;ao=2;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C9294T;aa_name=p.Y3098Y;hgvs_nt=NC_045512.2:g.9294C>T;hgvs_aa=YP_009724389.1:p.Tyr3098Tyr;hgvs_alias=YP_009724389.1:Tyr335Tyr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.043478260869565216;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	9565	9565	.	+	.	ID=ID_32;Name=F3100F;alias=F337F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=41;ao=5;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C9300T;aa_name=p.F3100F;hgvs_nt=NC_045512.2:g.9300C>T;hgvs_aa=YP_009724389.1:p.Phe3100Phe;hgvs_alias=YP_009724389.1:Phe337Phe;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.10869565217391304;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	9738	9738	.	+	.	ID=ID_33;Name=S3158T;alias=S395T;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=G;Variant_seq=C;nt_name=g.G9473C;aa_name=p.S3158T;hgvs_nt=NC_045512.2:g.9473G>C;hgvs_aa=YP_009724389.1:p.Ser3158Thr;hgvs_alias=YP_009724389.1:Ser395Thr;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	9967	9967	.	+	.	ID=ID_34;Name=L3234L;alias=L471L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=33;ao=13;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C9702T;aa_name=p.L3234L;hgvs_nt=NC_045512.2:g.9702C>T;hgvs_aa=YP_009724389.1:p.Leu3234Leu;hgvs_alias=YP_009724389.1:Leu471Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.2826086956521739;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	10712	10712	.	+	.	ID=ID_35;Name=L3483F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=41;ao=5;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C10447T;aa_name=p.L3483F;hgvs_nt=NC_045512.2:g.10447C>T;hgvs_aa=YP_009724389.1:p.Leu3483Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.10869565217391304;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	10969	10969	.	+	.	ID=ID_36;Name=F3568F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=43;ao=2;dp=45;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C10704T;aa_name=p.F3568F;hgvs_nt=NC_045512.2:g.10704C>T;hgvs_aa=YP_009724389.1:p.Phe3568Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.044444444444444446;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11345	11345	.	+	.	ID=ID_37;Name=L3694F;alias=L125F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=43;ao=3;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C11080T;aa_name=p.L3694F;hgvs_nt=NC_045512.2:g.11080C>T;hgvs_aa=YP_009724389.1:p.Leu3694Phe;hgvs_alias=YP_009724389.1:Leu125Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06521739130434782;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11455	11455	.	+	.	ID=ID_38;Name=A3730A;alias=A161A;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=45;ao=1;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C11190T;aa_name=p.A3730A;hgvs_nt=NC_045512.2:g.11190C>T;hgvs_aa=YP_009724389.1:p.Ala3730Ala;hgvs_alias=YP_009724389.1:Ala161Ala;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021739130434782608;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11674	11674	.	+	.	ID=ID_39;Name=Y3803Y;alias=Y234Y;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=45;ao=1;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C11409T;aa_name=p.Y3803Y;hgvs_nt=NC_045512.2:g.11409C>T;hgvs_aa=YP_009724389.1:p.Tyr3803Tyr;hgvs_alias=YP_009724389.1:Tyr234Tyr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021739130434782608;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11782	11782	.	+	.	ID=ID_40;Name=K3839K;alias=K270K;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=41;ao=5;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A11517G;aa_name=p.K3839K;hgvs_nt=NC_045512.2:g.11517A>G;hgvs_aa=YP_009724389.1:p.Lys3839Lys;hgvs_alias=YP_009724389.1:Lys270Lys;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.10869565217391304;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11801	11801	.	+	.	ID=ID_41;Name=G3846S;alias=G277S;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=45;ao=1;dp=46;sample_size=49;Reference_seq=G;Variant_seq=A;nt_name=g.G11536A;aa_name=p.G3846S;hgvs_nt=NC_045512.2:g.11536G>A;hgvs_aa=YP_009724389.1:p.Gly3846Ser;hgvs_alias=YP_009724389.1:Gly277Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021739130434782608;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11900	11900	.	+	.	ID=ID_42;Name=L3879F;alias=L20F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp7;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3860..3942;ro=41;ao=5;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C11635T;aa_name=p.L3879F;hgvs_nt=NC_045512.2:g.11635C>T;hgvs_aa=YP_009724389.1:p.Leu3879Phe;hgvs_alias=YP_009724389.1:Leu20Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.10869565217391304;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	12473	12473	.	+	.	ID=ID_43;Name=L4070L;alias=L128L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp8;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3943..4140;ro=41;ao=5;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C12208T;aa_name=p.L4070L;hgvs_nt=NC_045512.2:g.12208C>T;hgvs_aa=YP_009724389.1:p.Leu4070Leu;hgvs_alias=YP_009724389.1:Leu128Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.10869565217391304;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	13019	13019	.	+	.	ID=ID_44;Name=L4252L;alias=L112L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp9;mat_pep_desc=ssRNA-binding protein%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:4141..4253;ro=25;ao=20;dp=45;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C12754T;aa_name=p.L4252L;hgvs_nt=NC_045512.2:g.12754C>T;hgvs_aa=YP_009724389.1:p.Leu4252Leu;hgvs_alias=YP_009724389.1:Leu112Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4444444444444444;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	13176	13176	.	+	.	ID=ID_45;Name=T4304I;alias=T51I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp10;mat_pep_desc=nsp10_CysHis%3B formerly known as growth-factor-like protein (GFL)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:4254..4392;ro=44;ao=2;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C12911T;aa_name=p.T4304I;hgvs_nt=NC_045512.2:g.12911C>T;hgvs_aa=YP_009724389.1:p.Thr4304Ile;hgvs_alias=YP_009724389.1:Thr51Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.043478260869565216;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	13487	13487	.	+	.	ID=ID_46;Name=A4408V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=45;ao=1;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C13223T;aa_name=p.A4408V;hgvs_nt=NC_045512.2:g.13223C>T;hgvs_aa=YP_009724389.1:p.Ala4408Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021739130434782608;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	13713	13713	.	+	.	ID=ID_47;Name=K4483K;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=G;Variant_seq=A;nt_name=g.G13449A;aa_name=p.K4483K;hgvs_nt=NC_045512.2:g.13449G>A;hgvs_aa=YP_009724389.1:p.Lys4483Lys;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	14408	14408	.	+	.	ID=ID_48;Name=P4715L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C14144T;aa_name=p.P4715L;hgvs_nt=NC_045512.2:g.14144C>T;hgvs_aa=YP_009724389.1:p.Pro4715Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	14649	14649	.	+	.	ID=ID_49;Name=N4795N;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=43;ao=3;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C14385T;aa_name=p.N4795N;hgvs_nt=NC_045512.2:g.14385C>T;hgvs_aa=YP_009724389.1:p.Asn4795Asn;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06521739130434782;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	15513	15513	.	+	.	ID=ID_50;Name=N5083N;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=41;ao=5;dp=46;sample_size=49;Reference_seq=T;Variant_seq=C;nt_name=g.T15249C;aa_name=p.N5083N;hgvs_nt=NC_045512.2:g.15249T>C;hgvs_aa=YP_009724389.1:p.Asn5083Asn;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.10869565217391304;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	15656	15656	.	+	.	ID=ID_51;Name=T5131I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=44;ao=2;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C15392T;aa_name=p.T5131I;hgvs_nt=NC_045512.2:g.15392C>T;hgvs_aa=YP_009724389.1:p.Thr5131Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.043478260869565216;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	15732	15732	.	+	.	ID=ID_52;Name=V5156V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=41;ao=5;dp=46;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G15468T;aa_name=p.V5156V;hgvs_nt=NC_045512.2:g.15468G>T;hgvs_aa=YP_009724389.1:p.Val5156Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.10869565217391304;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	15828	15828	.	+	.	ID=ID_53;Name=E5188D;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=45;ao=1;dp=46;sample_size=49;Reference_seq=A;Variant_seq=T;nt_name=g.A15564T;aa_name=p.E5188D;hgvs_nt=NC_045512.2:g.15564A>T;hgvs_aa=YP_009724389.1:p.Glu5188Asp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021739130434782608;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	16289	16289	.	+	.	ID=ID_54;Name=A5342V;alias=A18V;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=44;ao=2;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C16025T;aa_name=p.A5342V;hgvs_nt=NC_045512.2:g.16025C>T;hgvs_aa=YP_009724389.1:p.Ala5342Val;hgvs_alias=YP_009724389.1:Ala18Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.043478260869565216;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	16394	16394	.	+	.	ID=ID_55;Name=P5377L;alias=P53L;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C16130T;aa_name=p.P5377L;hgvs_nt=NC_045512.2:g.16130C>T;hgvs_aa=YP_009724389.1:p.Pro5377Leu;hgvs_alias=YP_009724389.1:Pro53Leu;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	17014	17014	.	+	.	ID=ID_56;Name=D5584Y;alias=D260Y;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G16750T;aa_name=p.D5584Y;hgvs_nt=NC_045512.2:g.16750G>T;hgvs_aa=YP_009724389.1:p.Asp5584Tyr;hgvs_alias=YP_009724389.1:Asp260Tyr;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	17964	17964	.	+	.	ID=ID_57;Name=M5900I;alias=M576I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=44;ao=2;dp=46;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G17700T;aa_name=p.M5900I;hgvs_nt=NC_045512.2:g.17700G>T;hgvs_aa=YP_009724389.1:p.Met5900Ile;hgvs_alias=YP_009724389.1:Met576Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.043478260869565216;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	17977	17977	.	+	.	ID=ID_58;Name=L5905F;alias=L581F;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=45;ao=1;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C17713T;aa_name=p.L5905F;hgvs_nt=NC_045512.2:g.17713C>T;hgvs_aa=YP_009724389.1:p.Leu5905Phe;hgvs_alias=YP_009724389.1:Leu581Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021739130434782608;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	18131	18131	.	+	.	ID=ID_59;Name=T5956I;alias=T31I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=44;ao=2;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C17867T;aa_name=p.T5956I;hgvs_nt=NC_045512.2:g.17867C>T;hgvs_aa=YP_009724389.1:p.Thr5956Ile;hgvs_alias=YP_009724389.1:Thr31Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.043478260869565216;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	18171	18171	.	+	.	ID=ID_60;Name=G5969G;alias=G44G;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=42;ao=4;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C17907T;aa_name=p.G5969G;hgvs_nt=NC_045512.2:g.17907C>T;hgvs_aa=YP_009724389.1:p.Gly5969Gly;hgvs_alias=YP_009724389.1:Gly44Gly;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.08695652173913043;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	19398	19398	.	+	.	ID=ID_61;Name=E6378D;alias=E453D;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=37;ao=5;dp=42;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G19134T;aa_name=p.E6378D;hgvs_nt=NC_045512.2:g.19134G>T;hgvs_aa=YP_009724389.1:p.Glu6378Asp;hgvs_alias=YP_009724389.1:Glu453Asp;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.11904761904761904;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	19524	19524	.	+	.	ID=ID_62;Name=L6420L;alias=L495L;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=41;ao=1;dp=42;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C19260T;aa_name=p.L6420L;hgvs_nt=NC_045512.2:g.19260C>T;hgvs_aa=YP_009724389.1:p.Leu6420Leu;hgvs_alias=YP_009724389.1:Leu495Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.023809523809523808;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	20668	20668	.	+	.	ID=ID_63;Name=A6802T;alias=A4T;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp16;mat_pep_desc=nsp16_OMT%3B 2'-o-MT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6799..7096;ro=45;ao=1;dp=46;sample_size=49;Reference_seq=G;Variant_seq=A;nt_name=g.G20404A;aa_name=p.A6802T;hgvs_nt=NC_045512.2:g.20404G>A;hgvs_aa=YP_009724389.1:p.Ala6802Thr;hgvs_alias=YP_009724389.1:Ala4Thr;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021739130434782608;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	20762	20762	.	+	.	ID=ID_64;Name=T6833I;alias=T35I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp16;mat_pep_desc=nsp16_OMT%3B 2'-o-MT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6799..7096;ro=45;ao=1;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C20498T;aa_name=p.T6833I;hgvs_nt=NC_045512.2:g.20498C>T;hgvs_aa=YP_009724389.1:p.Thr6833Ile;hgvs_alias=YP_009724389.1:Thr35Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021739130434782608;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	20775	20775	.	+	.	ID=ID_65;Name=G6837G;alias=G39G;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp16;mat_pep_desc=nsp16_OMT%3B 2'-o-MT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6799..7096;ro=41;ao=5;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C20511T;aa_name=p.G6837G;hgvs_nt=NC_045512.2:g.20511C>T;hgvs_aa=YP_009724389.1:p.Gly6837Gly;hgvs_alias=YP_009724389.1:Gly39Gly;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.10869565217391304;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	20827	20827	.	+	.	ID=ID_66;Name=L6855L;alias=L57L;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp16;mat_pep_desc=nsp16_OMT%3B 2'-o-MT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6799..7096;ro=45;ao=1;dp=46;sample_size=49;Reference_seq=T;Variant_seq=C;nt_name=g.T20563C;aa_name=p.L6855L;hgvs_nt=NC_045512.2:g.20563T>C;hgvs_aa=YP_009724389.1:p.Leu6855Leu;hgvs_alias=YP_009724389.1:Leu57Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021739130434782608;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21575	21575	.	+	.	ID=ID_67;Name=L5F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=44;ao=1;dp=45;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C13T;aa_name=p.L5F;hgvs_nt=NC_045512.2:g.13C>T;hgvs_aa=YP_009724390.1:p.Leu5Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.022222222222222223;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21575	21575	.	+	.	ID=ID_67;Name=L5F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=44;ao=1;dp=45;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C13T;aa_name=p.L5F;hgvs_nt=NC_045512.2:g.13C>T;hgvs_aa=YP_009724390.1:p.Leu5Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.022222222222222223;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21575	21575	.	+	.	ID=ID_67;Name=L5F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=44;ao=1;dp=45;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C13T;aa_name=p.L5F;hgvs_nt=NC_045512.2:g.13C>T;hgvs_aa=YP_009724390.1:p.Leu5Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.022222222222222223;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_68;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=45;dp=45;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=W152C,L452R;function_description=14 of 34 RBD-specific mAbs showed reduced neutralization to the B.1.427/B.1.429 variant pseudotype.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_69;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=45;dp=45;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=;function_description=The S13I mutation dampened binding of 5 mAbs and abrogated binding of 5 additional mAbs out of 11 neutralizing mAbs evaluated. Predicted to shift the signal peptide cleavage site from S13-Q14 to C15-V16, which can affect NTD conformation.  PG: in saying S12F does not shift the signal peptide nor affect mAb binding, this manuscript appears to contradict the  text of McCallum et al.'s earlier 2021 manuscript stating that S12F *does* affected some mAb binding via putative signal peptide shift.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_70;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=45;dp=45;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=W152C;function_description=The B.1.427/B.1.429 S13I/W152C NTD did not bind to any NTD-directed neutralizing mAbs, which are known to target a single antigenic site (antigenic site i), whereas binding of the non-neutralizing S2L20 mAb to the NTD antigenic site iv was not affected by any mutants, confirming proper retention of folding.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_71;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=45;dp=45;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.42x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_72;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=45;dp=45;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,W152C,L452R;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.429 aka Epsilon) showed a 2.82x increase  in binding (KD) relative to D614G, indicating a strong marginal effect for L452R.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_68;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=45;dp=45;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=W152C,L452R;function_description=Swab samples N/NP viral RNA is approximately 2-fold higher in B.1.427/B.1.429 than in non-variant viruses.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_68;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=45;dp=45;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=W152C,L452R;function_description=Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was minimal against B.1.249 (1.7-fold). Neutralization against 10 convalescent plasma was somewhat poorer (3.1-fold).;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_68;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=45;dp=45;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1.full.pdf;citation=McCallum et al. (2021);comb_mutation=W152C,L452R;function_description=In 9 plasma collected 15 to 28 days after early 2020 infections, neutralization reduced 4.9-fold for B.1.427/B.1.429 compared to wildtype (D614G). In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for B.1.427/B.1.429 pseudotyped virus, as well as WT and other VOCs.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_68;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=45;dp=45;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=W152C,L452R;function_description=Antibody neutralization assays showed 6.7-fold resistence against 7/8 convalescent plasma.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_68;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=45;dp=45;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=W152C,L452R;function_description=Exhibits an estimated 18.6-24% increase in transmissibility relative to wild-type circulating strains. a.k.a. 20C/L452R or B.1.427/B.1.429.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	"ID=ID_68;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=45;dp=45;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1093/cid/ciab283;citation=Peng et al. (2021);comb_mutation=W152C,L452R;function_description=Lineages bearing these spike mutations comprised 54.4% of the total sequences from January, compared to 15.7% in November. Household  contacts exposed to the ""California"" or ""West Coast"" variants (B.1.427 and B.1.429) were at higher risk of infection compared  to household contacts exposed to lineages lacking these variants (0.36 vs 0.29, RR;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_71;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=45;dp=45;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_72;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=45;dp=45;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,W152C,L452R;function_description=This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding  (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset, indicating ablated marginal effect from L452R.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_68;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=45;dp=45;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=W152C,L452R;function_description=Using HIV pseudotype: Neutralization potency of 11 Moderna mRNA1273-elicited plasma (7-27 days post-2nd dose) was reduced ~2.8-fold compared to wildtype (D614G) S.  It was reduced ~4-fold in 14 Pfizer/BioNtech BNT162b2-elicited plasma (7-27 days post-2nd dose).  Using VSV pseudotype: we observed a 3-fold average reduction of Pfizer/BioNtech BNT162b2-elicited plasma neutralizing activity.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_72;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=45;dp=45;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=W152C,L452R,D614G;function_description=Pseudotyped B.1.1.429 virus has reduced neutralization activity vs wild type: 2.0x (30 sera Pfizer median 9  days post 2nd dose, 35 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_72;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=45;dp=45;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1;citation=Pegu et al (2021);comb_mutation=W152C,L452R,D614G;function_description=Detectable antibodies against B.1.1.7 in all samples at Day 43 and Day 209 using pseudotyped lentivirus neutralization in Moderna vaccinee cohort.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_72;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=45;dp=45;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=W152C,L452R,D614G;function_description=Neutralization efficiency (ID50) against B.1.1.427/429 reduced 2.1x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_72;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=45;dp=45;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=W152C,L452R,D614G;function_description=6 of 11 (55%) vaccine recipients (Moderna or Pfizer), showed 2x reduction in neutralization to a B.1.429 lineage virus.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_71;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=45;dp=45;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21600	21600	.	+	.	ID=ID_72;Name=S13I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=45;dp=45;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G38T;aa_name=p.S13I;hgvs_nt=NC_045512.2:g.38G>T;hgvs_aa=YP_009724390.1:p.Ser13Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,W152C,L452R;function_description=This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding  (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. [Stark contrast to 2.15x increase in binding by convalescent plasma 8 months post infection, presumably via memory B cell affinity maturation  against L452R effects] 1.12x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21622	21622	.	+	.	ID=ID_73;Name=T20T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=40;ao=5;dp=45;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C60T;aa_name=p.T20T;hgvs_nt=NC_045512.2:g.60C>T;hgvs_aa=YP_009724390.1:p.Thr20Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.1111111111111111;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_68;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=43;dp=43;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=S13I,L452R;function_description=14 of 34 RBD-specific mAbs showed reduced neutralization to the B.1.427/B.1.429 variant pseudotype.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_74;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=43;dp=43;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=;function_description=The W152C mutation reduced recognition of six NTD neutralizing mAbs, including a complete loss of binding for two of them, with a complementary pattern to that observed for S13I (also found in lineage B.1.427/B.1.429) out of 11 neutralizing mAbs evaluated.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_70;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=43;dp=43;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=S13I;function_description=The B.1.427/B.1.429 S13I/W152C NTD did not bind to any NTD-directed neutralizing mAbs, which are known to target a single antigenic site (antigenic site i), whereas binding of the non-neutralizing S2L20 mAb to the NTD antigenic site iv was not affected by any mutants, confirming proper retention of folding.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_75;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=43;dp=43;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_72;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=43;dp=43;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,S13I,L452R;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.429 aka Epsilon) showed a 2.82x increase  in binding (KD) relative to D614G, indicating a strong marginal effect for L452R.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_74;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=43;dp=43;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=;function_description=Pseudoviruses carrying the W152C mutation demonstrated small increases in cell entry compared to  D614G alone in 293T cells and human airway organoids.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_68;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=43;dp=43;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=S13I,L452R;function_description=Swab samples N/NP viral RNA is approximately 2-fold higher in B.1.427/B.1.429 than in non-variant viruses.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_68;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=43;dp=43;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=S13I,L452R;function_description=Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was minimal against B.1.249 (1.7-fold). Neutralization against 10 convalescent plasma was somewhat poorer (3.1-fold).;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_68;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=43;dp=43;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1.full.pdf;citation=McCallum et al. (2021);comb_mutation=S13I,L452R;function_description=In 9 plasma collected 15 to 28 days after early 2020 infections, neutralization reduced 4.9-fold for B.1.427/B.1.429 compared to wildtype (D614G). In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for B.1.427/B.1.429 pseudotyped virus, as well as WT and other VOCs.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_68;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=43;dp=43;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=S13I,L452R;function_description=Antibody neutralization assays showed 6.7-fold resistence against 7/8 convalescent plasma.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_68;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=43;dp=43;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=S13I,L452R;function_description=Exhibits an estimated 18.6-24% increase in transmissibility relative to wild-type circulating strains. a.k.a. 20C/L452R or B.1.427/B.1.429.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	"ID=ID_68;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=43;dp=43;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1093/cid/ciab283;citation=Peng et al. (2021);comb_mutation=S13I,L452R;function_description=Lineages bearing these spike mutations comprised 54.4% of the total sequences from January, compared to 15.7% in November. Household  contacts exposed to the ""California"" or ""West Coast"" variants (B.1.427 and B.1.429) were at higher risk of infection compared  to household contacts exposed to lineages lacking these variants (0.36 vs 0.29, RR;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_75;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=43;dp=43;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.15x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_72;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=43;dp=43;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,S13I,L452R;function_description=This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding  (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset, indicating ablated marginal effect from L452R.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_68;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=43;dp=43;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=S13I,L452R;function_description=Using HIV pseudotype: Neutralization potency of 11 Moderna mRNA1273-elicited plasma (7-27 days post-2nd dose) was reduced ~2.8-fold compared to wildtype (D614G) S.  It was reduced ~4-fold in 14 Pfizer/BioNtech BNT162b2-elicited plasma (7-27 days post-2nd dose).  Using VSV pseudotype: we observed a 3-fold average reduction of Pfizer/BioNtech BNT162b2-elicited plasma neutralizing activity.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_72;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=43;dp=43;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=S13I,L452R,D614G;function_description=Pseudotyped B.1.1.429 virus has reduced neutralization activity vs wild type: 2.0x (30 sera Pfizer median 9  days post 2nd dose, 35 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_72;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=43;dp=43;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1;citation=Pegu et al (2021);comb_mutation=S13I,L452R,D614G;function_description=Detectable antibodies against B.1.1.7 in all samples at Day 43 and Day 209 using pseudotyped lentivirus neutralization in Moderna vaccinee cohort.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_72;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=43;dp=43;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=S13I,L452R,D614G;function_description=Neutralization efficiency (ID50) against B.1.1.427/429 reduced 2.1x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_72;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=43;dp=43;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=S13I,L452R,D614G;function_description=6 of 11 (55%) vaccine recipients (Moderna or Pfizer), showed 2x reduction in neutralization to a B.1.429 lineage virus.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_75;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=43;dp=43;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.03x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.32x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22018	22018	.	+	.	ID=ID_72;Name=W152C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=43;dp=43;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G456T;aa_name=p.W152C;hgvs_nt=NC_045512.2:g.456G>T;hgvs_aa=YP_009724390.1:p.Trp152Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,S13I,L452R;function_description=This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding  (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. [Stark contrast to 2.15x increase in binding by convalescent plasma 8 months post infection, presumably via memory B cell affinity maturation  against L452R effects] 1.12x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22402	22402	.	+	.	ID=ID_76;Name=N280N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=44;ao=2;dp=46;sample_size=49;Reference_seq=T;Variant_seq=C;nt_name=g.T840C;aa_name=p.N280N;hgvs_nt=NC_045512.2:g.840T>C;hgvs_aa=YP_009724390.1:p.Asn280Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.043478260869565216;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22597	22597	.	+	.	ID=ID_77;Name=T345T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=25;ao=21;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C1035T;aa_name=p.T345T;hgvs_nt=NC_045512.2:g.1035C>T;hgvs_aa=YP_009724390.1:p.Thr345Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.45652173913043476;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_78;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1.full.pdf;citation=Motozono et al. (2021);comb_mutation=;function_description=L452R derivative virus did not induce IFN-gamma expression even at the highest concentration tested (10 nM) in two different A*24:02 convalescent sera  donor plasma (linear epitope NYNYLYRLF 448,456).;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_78;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation=;function_description=~20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against monoclonal antibody VH ab6.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_78;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=;function_description=10 of 14 RBD-specific mAbs that showed at least 10-fold reduced neutralization of B.1.427/B.1.429 variant pseudotype (S13I, W152C, and L452R) were also found to poorly bind to just a L452R RBD mutant, demonstrating a role for this mutation as an escape mechanism for certain RBD-targeting mAbs.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_68;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=S13I,W152C;function_description=14 of 34 RBD-specific mAbs showed reduced neutralization to the B.1.427/B.1.429 variant pseudotype.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_78;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_78;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.sciencedirect.com/science/article/abs/pii/S0092867420308771;citation=Li et al. (2020);comb_mutation=;function_description=Resistent to some neutralizing antibodies: mAbs X593 and P2B-2F6;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_79;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_72;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,S13I,W152C;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.429 aka Epsilon) showed a 2.82x increase  in binding (KD) relative to D614G, indicating a strong marginal effect for L452R.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_78;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=~1.7-fold increase in binding affinity vs wild type.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_78;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferriera et al (2021);comb_mutation=;function_description=This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. [listed as L454R in Figure, but L452R in text, also text  suggests not statistucally significant, but error bars say otherwise in Figure 4];heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_78;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=Increased stability of RBD expression in yeast, suggesting increased Spike protein stability.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_78;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=;function_description=We observed increased entry by pseudoviruses carrying the L452R mutation compared to D614G alone,  with a 6.7 to 22.5-fold increase in 293T cells and a 5.8 to 14.7-fold increase in human airway organoids.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_68;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=S13I,W152C;function_description=Swab samples N/NP viral RNA is approximately 2-fold higher in B.1.427/B.1.429 than in non-variant viruses.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_78;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=;function_description=Bamlanivimab (LY-CoV555) entirely lost its neutralizing activity due to the central location of L452R in the epitopes recognized by this mAb. Regdanvimab (CT-P59), and to a smaller extent etesevimab, showed a reduction in neutralization potency.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_78;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Bamlanivimab (LY-CoV555) lost ~5x binding against this isolated mutation. Cligavimab lost ~4x binding against this isolated mutation. Regdanvimab lost ~4x binding against this isolated mutation.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_79;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=D614G;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_68;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=S13I,W152C;function_description=Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was minimal against B.1.249 (1.7-fold). Neutralization against 10 convalescent plasma was somewhat poorer (3.1-fold).;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_68;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1.full.pdf;citation=McCallum et al. (2021);comb_mutation=S13I,W152C;function_description=In 9 plasma collected 15 to 28 days after early 2020 infections, neutralization reduced 4.9-fold for B.1.427/B.1.429 compared to wildtype (D614G). In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for B.1.427/B.1.429 pseudotyped virus, as well as WT and other VOCs.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_78;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=;function_description=Observed ~2x decrease on average in 16 health workers' convalescent sera.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_68;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=S13I,W152C;function_description=Antibody neutralization assays showed 6.7-fold resistence against 7/8 convalescent plasma.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_78;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Ablation of neutralization capability of 3 of 4 convalescent sera tested, the other is significantly hindered.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_79;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=D614G;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a lower 3-fold increase];heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_68;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=S13I,W152C;function_description=Exhibits an estimated 18.6-24% increase in transmissibility relative to wild-type circulating strains. a.k.a. 20C/L452R or B.1.427/B.1.429.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	"ID=ID_68;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1093/cid/ciab283;citation=Peng et al. (2021);comb_mutation=S13I,W152C;function_description=Lineages bearing these spike mutations comprised 54.4% of the total sequences from January, compared to 15.7% in November. Household  contacts exposed to the ""California"" or ""West Coast"" variants (B.1.427 and B.1.429) were at higher risk of infection compared  to household contacts exposed to lineages lacking these variants (0.36 vs 0.29, RR;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_79;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_72;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,S13I,W152C;function_description=This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding  (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset, indicating ablated marginal effect from L452R.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_79;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=D614G;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_78;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferreira et al. (2021);comb_mutation=;function_description=Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. L452R conferred about a two-fold reduction in neutralisation by vaccine sera, but was not statistically significant with this sample size.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_68;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;citation=McCallum et al. (2021);comb_mutation=S13I,W152C;function_description=Using HIV pseudotype: Neutralization potency of 11 Moderna mRNA1273-elicited plasma (7-27 days post-2nd dose) was reduced ~2.8-fold compared to wildtype (D614G) S.  It was reduced ~4-fold in 14 Pfizer/BioNtech BNT162b2-elicited plasma (7-27 days post-2nd dose).  Using VSV pseudotype: we observed a 3-fold average reduction of Pfizer/BioNtech BNT162b2-elicited plasma neutralizing activity.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_72;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=S13I,W152C,D614G;function_description=Pseudotyped B.1.1.429 virus has reduced neutralization activity vs wild type: 2.0x (30 sera Pfizer median 9  days post 2nd dose, 35 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_72;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1;citation=Pegu et al (2021);comb_mutation=S13I,W152C,D614G;function_description=Detectable antibodies against B.1.1.7 in all samples at Day 43 and Day 209 using pseudotyped lentivirus neutralization in Moderna vaccinee cohort.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_72;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=S13I,W152C,D614G;function_description=Neutralization efficiency (ID50) against B.1.1.427/429 reduced 2.1x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_78;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2;citation=Jacobson et al. (2021);comb_mutation=;function_description=The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_72;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=S13I,W152C,D614G;function_description=6 of 11 (55%) vaccine recipients (Moderna or Pfizer), showed 2x reduction in neutralization to a B.1.429 lineage virus.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_78;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_78;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=;function_description=Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_78;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Class 2/3 antibody C628 and class 2 antibody C643 selected for the emergence of the L452R mutation in vitro.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_78;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.32 fold;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_78;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is -0.67 kcal/mol (i.e. destabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_79;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22917	22917	.	+	.	ID=ID_72;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=T;Variant_seq=G;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,S13I,W152C;function_description=This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding  (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. [Stark contrast to 2.15x increase in binding by convalescent plasma 8 months post infection, presumably via memory B cell affinity maturation  against L452R effects] 1.12x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23191	23191	.	+	.	ID=ID_80;Name=F543F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=44;ao=2;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C1629T;aa_name=p.F543F;hgvs_nt=NC_045512.2:g.1629C>T;hgvs_aa=YP_009724390.1:p.Phe543Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.043478260869565216;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23296	23296	.	+	.	ID=ID_81;Name=D578D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=45;ao=1;dp=46;sample_size=49;Reference_seq=T;Variant_seq=C;nt_name=g.T1734C;aa_name=p.D578D;hgvs_nt=NC_045512.2:g.1734T>C;hgvs_aa=YP_009724390.1:p.Asp578Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021739130434782608;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_82;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://www.medrxiv.org/content/10.1101/2021.05.08.21256775v1;citation=Landis et al. (2021);comb_mutation=;function_description=Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_82;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_67;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L5F;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_71;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=S13I;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.42x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_75;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=W152C;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_79;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L452R;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_72;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=S13I,W152C,L452R;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.429 aka Epsilon) showed a 2.82x increase  in binding (KD) relative to D614G, indicating a strong marginal effect for L452R.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_82;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.07.012;citation=Li et al. (2020);comb_mutation=;function_description=In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_82;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_82;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_82;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1;citation=Barrett et al. (2021);comb_mutation=;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_82;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.nature.com/articles/s41467-020-19808-4;citation=Zhang et l. (2020);comb_mutation=;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_82;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.nature.com/articles/s41467-021-21118-2;citation=Ozono et al. (2020);comb_mutation=;function_description=Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_82;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.7554/elife.65365;citation=Daniloski et al. (2021);comb_mutation=;function_description=The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_82;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=tissue specific neutralization;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation=;function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_82;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.nature.com/articles/s41586-020-2895-3;citation=Plante et al. (2020);comb_mutation=;function_description=Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_79;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=L452R;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_79;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=L452R;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a lower 3-fold increase];heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_67;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L5F;function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_71;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=S13I;function_description=1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_75;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=W152C;function_description=1.15x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_79;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L452R;function_description=2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_72;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=S13I,W152C,L452R;function_description=This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding  (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset, indicating ablated marginal effect from L452R.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_79;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1;citation=Wilhelm et al. (2021);comb_mutation=L452R;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_82;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=;function_description=Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_82;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=;function_description=Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_72;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=S13I,W152C,L452R;function_description=Pseudotyped B.1.1.429 virus has reduced neutralization activity vs wild type: 2.0x (30 sera Pfizer median 9  days post 2nd dose, 35 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_72;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1;citation=Pegu et al (2021);comb_mutation=S13I,W152C,L452R;function_description=Detectable antibodies against B.1.1.7 in all samples at Day 43 and Day 209 using pseudotyped lentivirus neutralization in Moderna vaccinee cohort.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_72;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=S13I,W152C,L452R;function_description=Neutralization efficiency (ID50) against B.1.1.427/429 reduced 2.1x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_72;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;citation=Deng et al. (2021);comb_mutation=S13I,W152C,L452R;function_description=6 of 11 (55%) vaccine recipients (Moderna or Pfizer), showed 2x reduction in neutralization to a B.1.429 lineage virus.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_82;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.nature.com/articles/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_82;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/;citation=Yurkovetskiy et al. (2020);comb_mutation=;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_82;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2;citation=Weissman et al. (2020);comb_mutation=;function_description=Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_82;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_67;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L5F;function_description=1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_71;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=S13I;function_description=1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_75;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=W152C;function_description=1.03x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.32x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_79;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L452R;function_description=1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_72;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=S13I,W152C,L452R;function_description=This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding  (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. [Stark contrast to 2.15x increase in binding by convalescent plasma 8 months post infection, presumably via memory B cell affinity maturation  against L452R effects] 1.12x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24157	24157	.	+	.	ID=ID_83;Name=L865L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=42;ao=3;dp=45;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C2595T;aa_name=p.L865L;hgvs_nt=NC_045512.2:g.2595C>T;hgvs_aa=YP_009724390.1:p.Leu865Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06666666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25317	25317	.	+	.	ID=ID_84;Name=S1252F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=40;ao=6;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C3755T;aa_name=p.S1252F;hgvs_nt=NC_045512.2:g.3755C>T;hgvs_aa=YP_009724390.1:p.Ser1252Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.13043478260869565;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25467	25467	.	+	.	ID=ID_85;Name=P25P;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=40;ao=6;dp=46;sample_size=49;Reference_seq=T;Variant_seq=C;nt_name=g.T75C;aa_name=p.P25P;hgvs_nt=NC_045512.2:g.75T>C;hgvs_aa=YP_009724391.1:p.Pro25Pro;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.13043478260869565;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25492	25492	.	+	.	ID=ID_86;Name=T34A;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=45;ao=1;dp=46;sample_size=49;Reference_seq=A;Variant_seq=G;nt_name=g.A100G;aa_name=p.T34A;hgvs_nt=NC_045512.2:g.100A>G;hgvs_aa=YP_009724391.1:p.Thr34Ala;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021739130434782608;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25549	25549	.	+	.	ID=ID_87;Name=L53F;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=45;ao=1;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C157T;aa_name=p.L53F;hgvs_nt=NC_045512.2:g.157C>T;hgvs_aa=YP_009724391.1:p.Leu53Phe;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021739130434782608;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25563	25563	.	+	.	ID=ID_88;Name=Q57H;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G171T;aa_name=p.Q57H;hgvs_nt=NC_045512.2:g.171G>T;hgvs_aa=YP_009724391.1:p.Gln57His;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25702	25702	.	+	.	ID=ID_89;Name=P104S;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=42;ao=4;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C310T;aa_name=p.P104S;hgvs_nt=NC_045512.2:g.310C>T;hgvs_aa=YP_009724391.1:p.Pro104Ser;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.08695652173913043;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25844	25844	.	+	.	ID=ID_90;Name=T151I;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=33;ao=13;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C452T;aa_name=p.T151I;hgvs_nt=NC_045512.2:g.452C>T;hgvs_aa=YP_009724391.1:p.Thr151Ile;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.2826086956521739;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	26066	26066	.	+	.	ID=ID_91;Name=V225A;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=40;ao=6;dp=46;sample_size=49;Reference_seq=T;Variant_seq=C;nt_name=g.T674C;aa_name=p.V225A;hgvs_nt=NC_045512.2:g.674T>C;hgvs_aa=YP_009724391.1:p.Val225Ala;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.13043478260869565;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	26681	26681	.	+	.	ID=ID_92;Name=F53F;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C159T;aa_name=p.F53F;hgvs_nt=NC_045512.2:g.159C>T;hgvs_aa=YP_009724393.1:p.Phe53Phe;hgvs_alias=n/a;vcf_gene=M;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27263	27263	.	+	.	ID=ID_93;Name=T21I;alias=n/a;gene=ORF6;protein_name=ORF6 protein;protein_symbol=ORF6;protein_id=YP_009724394.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=44;ao=2;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C62T;aa_name=p.T21I;hgvs_nt=NC_045512.2:g.62C>T;hgvs_aa=YP_009724394.1:p.Thr21Ile;hgvs_alias=n/a;vcf_gene=ORF6;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.043478260869565216;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27494	27494	.	+	.	ID=ID_94;Name=P34L;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=44;ao=2;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C101T;aa_name=p.P34L;hgvs_nt=NC_045512.2:g.101C>T;hgvs_aa=YP_009724395.1:p.Pro34Leu;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.043478260869565216;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27882	27882	.	+	.	ID=ID_95;Name=A43T;alias=n/a;gene=ORF7b;protein_name=ORF7b;protein_symbol=ORF7b;protein_id=YP_009725318.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=33;ao=13;dp=46;sample_size=49;Reference_seq=G;Variant_seq=A;nt_name=g.G127A;aa_name=p.A43T;hgvs_nt=NC_045512.2:g.127G>A;hgvs_aa=YP_009725318.1:p.Ala43Thr;hgvs_alias=n/a;vcf_gene=ORF7b;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.2826086956521739;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27911	27911	.	+	.	ID=ID_96;Name=F6F;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=44;ao=2;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C18T;aa_name=p.F6F;hgvs_nt=NC_045512.2:g.18C>T;hgvs_aa=YP_009724396.1:p.Phe6Phe;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.043478260869565216;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27994	27994	.	+	.	ID=ID_97;Name=D34V;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=42;ao=4;dp=46;sample_size=49;Reference_seq=A;Variant_seq=T;nt_name=g.A101T;aa_name=p.D34V;hgvs_nt=NC_045512.2:g.101A>T;hgvs_aa=YP_009724396.1:p.Asp34Val;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.08695652173913043;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28087	28087	.	+	.	ID=ID_98;Name=A65V;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=25;ao=21;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C194T;aa_name=p.A65V;hgvs_nt=NC_045512.2:g.194C>T;hgvs_aa=YP_009724396.1:p.Ala65Val;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.45652173913043476;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28134	28134	.	+	.	ID=ID_99;Name=V81I;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=45;ao=1;dp=46;sample_size=49;Reference_seq=G;Variant_seq=A;nt_name=g.G241A;aa_name=p.V81I;hgvs_nt=NC_045512.2:g.241G>A;hgvs_aa=YP_009724396.1:p.Val81Ile;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021739130434782608;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28272	28272	.	+	.	ID=ID_100;Name=g.A-2T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=A;Variant_seq=T;nt_name=g.A-2T;aa_name=;hgvs_nt=NC_045512.2:g.2A>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=N;mutation_type=;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28471	28471	.	+	.	ID=ID_101;Name=F66F;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=42;ao=4;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C198T;aa_name=p.F66F;hgvs_nt=NC_045512.2:g.198C>T;hgvs_aa=YP_009724397.2:p.Phe66Phe;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.08695652173913043;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28487	28487	.	+	.	ID=ID_102;Name=V72I;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=45;ao=1;dp=46;sample_size=49;Reference_seq=G;Variant_seq=A;nt_name=g.G214A;aa_name=p.V72I;hgvs_nt=NC_045512.2:g.214G>A;hgvs_aa=YP_009724397.2:p.Val72Ile;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021739130434782608;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28887	28887	.	+	.	ID=ID_103;Name=T205I;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=46;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C614T;aa_name=p.T205I;hgvs_nt=NC_045512.2:g.614C>T;hgvs_aa=YP_009724397.2:p.Thr205Ile;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29179	29179	.	+	.	ID=ID_104;Name=P302P;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=45;ao=1;dp=46;sample_size=49;Reference_seq=G;Variant_seq=T;nt_name=g.G906T;aa_name=p.P302P;hgvs_nt=NC_045512.2:g.906G>T;hgvs_aa=YP_009724397.2:p.Pro302Pro;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021739130434782608;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29284	29284	.	+	.	ID=ID_105;Name=I337I;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=41;ao=5;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C1011T;aa_name=p.I337I;hgvs_nt=NC_045512.2:g.1011C>T;hgvs_aa=YP_009724397.2:p.Ile337Ile;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.10869565217391304;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29362	29362	.	+	.	ID=ID_106;Name=F363F;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=3;ao=43;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C1089T;aa_name=p.F363F;hgvs_nt=NC_045512.2:g.1089C>T;hgvs_aa=YP_009724397.2:p.Phe363Phe;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9347826086956522;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29555	29555	.	+	.	ID=ID_107;Name=g.C-3T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=45;ao=1;dp=46;sample_size=49;Reference_seq=C;Variant_seq=T;nt_name=g.C-3T;aa_name=;hgvs_nt=NC_045512.2:g.3C>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF10;mutation_type=;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021739130434782608;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	del	29755	29755	.	+	.	ID=ID_108;Name=g.GAGTGTAC29755G;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=40;ao=5;dp=45;sample_size=49;Reference_seq=GAGTGTAC;Variant_seq=G;nt_name=g.GAGTGTAC29755G;aa_name=;hgvs_nt=n/a;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=B.1.427;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.1111111111111111;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Epsilon;variant_type=VOI;voi_designation_date=05-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
